Maravai LifeSciences, Inc. announced that its Board of Directors has appointed William “Trey” Martin, III as its chief executive officer (CEO). Mr. Martin comes to Maravai most recently from Danaher Corporation, where he was the Senior Vice President of New Business, Genomic Medicine. Maravai's first CEO and co-founder Carl Hull will directly support Mr. Martin during this leadership transition and will remain with Maravai as Executive Chairman of the Board where he will continue to guide the company's long-term strategy.

Mr. Martin brings more than 25 years of executive leadership experience in life sciences operations, engineering, sales and marketing. He was most recently Senior Vice President, Genomic Medicines, at Danaher Corporation. Mr. Martin originally joined Danaher with the acquisition of Integrated DNA Technologies (IDT) in 2018, and served as President of the IDT business there for over three years.

Prior to its acquisition, Mr. Martin held positions of increasing responsibility over more than two decades at IDT and contributed to the consistent growth and competitiveness of the company's primary oligo synthesis business through organic and inorganic growth investments. Mr. Martin holds a Bachelor's in biochemistry from the University of Iowa. Mr. Hull will remain involved with the strategic direction of Maravai as the Executive Chairman of the Board and will work together with Mr. Martin to help drive the Company forward.

His focus will also be on supporting Mr. Martin throughout this leadership transition and leveraging their complementary skillsets to further improve the business. Mr. Hull co-founded Maravai in 2014. The Company will further discuss the management transition plan on its third quarter 2022 earnings call currently scheduled for November 2, 2022.